Sign in
Manoj Eradath

Manoj Eradath

Vice President and Equity Analyst at Jefferies Financial Group Inc.

New York, NY, US

Manoj Eradath is a Vice President and Equity Analyst at Jefferies LLC, specializing in research on the technology sector, with a particular focus on companies operating in the IT services and consulting domains. Throughout his career, he has covered major firms such as Infosys, Tata Consultancy Services, and Wipro, delivering analysis influential to institutional investors, though specific performance rankings or TipRanks data are not publicly available. Eradath began his professional financial career in the mid-2010s and has held his current position at Jefferies since at least 2021, having previously gained experience at other financial institutions in related analytical roles. He holds FINRA registrations with Series 7 and Series 63 licenses, underscoring his professional qualifications and regulatory standing.

Manoj Eradath's questions to BioNTech (BNTX) leadership

Question · Q3 2025

Manoj Eradath asked if the recent Harmony III trial changes, which involve separate statistical analysis for squamous and non-squamous NSCLC populations, would impact the powering of the ROSETTA 02 trial (BNT327 plus chemotherapy) for PFS and OS endpoints in its Phase III portion, and if any trial design changes are anticipated.

Answer

Özlem Türeci, Chief Medical Officer and Co-founder, responded that BioNTech constantly re-evaluates its statistical analysis plans for ongoing trials based on new data and will specifically look into the implications for the ROSETTA 02 trial.

Ask follow-up questions

Question · Q3 2025

Manoj Eradath, on behalf of Akash Tewari, referenced recent changes in the Harmony III trial for first-line NSCLC, which now separates primary PFS and OS statistical analysis for squamous and non-squamous populations. He asked if BioNTech believes the Rosetta-Lung-02 trial for BNT327 plus chemo is still sufficiently powered for PFS and OS endpoints in its phase 3 portion, and if any trial design changes are anticipated.

Answer

Özlem Türeci, Chief Medical Officer and Co-founder, responded that BioNTech constantly re-evaluates its statistical analysis plans for ongoing trials based on new data and will specifically review the Rosetta-Lung-02 trial in light of this new information.

Ask follow-up questions

Manoj Eradath's questions to Zymeworks (ZYME) leadership

Question · Q4 2024

Manoj Eradath, on behalf of Akash Tewari, asked about the delay in the HERIZON-GEA-01 trial readout, questioning if it was due to enrollment speed or event rates, and inquired about potential patient selection bias regarding PD-1 status.

Answer

Chair and CEO Kenneth Galbraith declined to speculate on the trial specifics, referring the question back to their partner Jazz Pharmaceuticals, who provided an update on the guidance and rationale during their own recent earnings call.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%